METTL1 and thyroid cancer: Aberrant METTL1 expression has been observed across multiple cancer types—including lung, liver, colorectal, gastric, breast, cholangiocarcinoma, esophageal, glioma, head and neck, and thyroid cancers-where it promotes tumor proliferation, metastasis, therapy resistance, and metabolic reprogramming.